Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: Relation with serotonin levels

European Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2008, Pages 1-8

  Rossi, Cristiana ^a   Pini, Luigi Alberto ^b   Cupini, Maria Letizia ^c   Calabresi, Paolo ^a,d   Sarchielli, Paola ^a,e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Chronic headache; Endocannabinoids; Medication overuse headache; Serotonin

Indexed keywords

ACYLGLYCEROL; ANANDAMIDE; BUTALBITAL; CAFFEINE; DICLOFENAC; ENDOCANNABINOID; INDOMETACIN; KETOROLAC; NAPROXEN; NIMESULIDE; PARACETAMOL; PIROXICAM; PROCHLORPERAZINE; PROPYPHENAZONE; SEROTONIN;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEROTONINERGIC SYSTEM; STATISTICAL ANALYSIS; THROMBOCYTE; TRANSFORMED MIGRAINE;

ADULT; ARACHIDONIC ACIDS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CHRONIC DISEASE; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HEADACHE DISORDERS, SECONDARY; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITHOUT AURA; POLYUNSATURATED ALKAMIDES; SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 38049012986     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0391-4     Document Type: Article

References (47)

1. Pascual J, Colas R, Castillo J (2001) Epidemiology of chronic daily headache. Curr Pain Headache Rep 5:529-536
2. Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475-483
3. Boes CJ, Black DF, Dodick DW (2006) Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 26:232-241
4. Srikiatkhachorn A (2001) Pathophysiology of chronic daily headache. Curr Pain Headache Rep 5:537-544
5. Welch KM (2003) Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol Sci 24(Suppl 2):S149-S153
6. Cupini LM, Calabresi P (2005) Medication-overuse headache: pathophysiological insights. J Headache Pain 6:199-202
7. Calabresi P, Cupini LM (2005) Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 26:62-68
8. Fumal A, Laureys S, Di Clemente L, Boly M, Bohotin V, Vandenheede M, Coppola G, Salmon E, Kupers R, Schoenen J (2006) Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 129:543-550
9. D'Andrea G, Cananzi AR, Perini F, Hasselmark L (1995) Platelet models and their possibile usefulness in the study of migraine pathogenesis. Cephalagia 15:265-271
10. Gallai V, Floridi A, Mazzotta G, Codini M, Tognoloni M, Ambrosini P et al (1996) L-arginine/nitric oxide patway activation in platelets of migraine with and without aura patients. Acta Neurol Scand 94:151-160
11. Hering R, Glover V, Pattichis K, Catarci T, Steiner TJ (1993) 5HT in migraine patients with medication-induced headache. Cephalalgia 13:410-412
12. Srikiatkhachorn A, Govitrapong P, Limthavon C (1994) Up-regulation of 5-HT2 serotonin receptor: a possible mechanism of transformed migraine. Headache 34:8-11
13. Srikiatkhachorn A, Maneesri S, Govitrapong P, Kasantikul V (1998) Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets. Headache 38:43-49
14. Sarchielli P, Alberti A, Russo S, Codini M, Panico R, Floridi A, Gallai V (1999) Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 19:810-816
15. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277-281
16. Walker JM, Hohmann AG (2005) Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 168:509-554
17. Akerman S, Kaube H, Goadsby PJ (2004) Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharm Exp Ther 309:56-63
18. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr (2003) Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99:955-960
19. Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I (1998) Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharmacol Bull 21:224-226
20. Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533-541
21. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316:969-982
22. Parolaro D, Vigano D, Rubino T (2005) Endocannabinoids and drug dependence. Curr Drug Targets CNS Neurol Disord 4:643-655
23. Maccarrone M, Bari M, Battista N, Finazzi-Agro A (2002) Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 1:53-63
24. Macarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A (2001) Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 268:819-825, Feb
25. Maccarrone M, Bari M, Principe DD, Finazzi-Agro A (2003) Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 89:340-347
26. Braud S, Bon C, Touqui L, Mounier C (2000) Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett 471:12-16
27. Berdyshev EV, Schmid PC, Krebsbach RJ, Schmid HH (2001) Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J 15:2171-2178
28. Cupini LM, Bari M, Battista N, Argiro G, Finazzi-Agro A, Calabresi P, Maccarrone M (2006) Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 26:277-281
29. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1):9-160
30. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Göbel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Steiner TJ, on behalf of the International Headache Society (2005) The international classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 25:460-465
31. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742-746
32. Lingjaerde O (1990) Blood platelets as a model system for studying serotonergic dysfunction and effects of antidepressants. Pharmacol Toxicol 66(Suppl 3):61-68
33. Uebelhack R, Franke L, Herold N, Plotkin M, Amthauer H, Felix R (2006) Brain and platelet serotonin transporter in humans-correlation between [123I]-ADAM SPECT and serotonergic measurements in platelets. Neurosci Lett 406:153-158, Epub 2006 Aug 24
34. Vogeser M, Hauer D, Christina Azad S, Huber E, Storr M, Schelling G (2006) Release of anandamide from blood cells. Clin Chem Lab Med 44:488-491
35. Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P (2007) Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 32:1384-1390
36. Akerman S, Holland PR, Goadsby PJ (2007) Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 320:64-71
37. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225-232
38. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, Fratta W (2007) An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 53:1-16
39. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81
40. Ferrer B, Bermúdez-Silva FJ, Bilbao A, Alvarez-Jaimes L, Sanchez-Vera I, Giuffrida A, Serrano A, Baixeras E, Khaturia S, Navarro M, Parsons LH, Piomelli D, Rodriguez de Fonseca F (2007) Regulation of brain anandamide by acute administration of ethanol. Biochem J 404:97-104
41. Beardsley PM, Thomas BF (2005) Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 16:275-296
42. Tucci SA, Halford JC, Harrold JA, Kirkham TC (2006) Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation. Curr Med Chem 13:2669-2680
43. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF (2002) A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99:8394-8399
44. Parrish JC, Nichols DE (2006) Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. J Neurochem 99:1164-1175
45. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102(51):18620-18625, Erratum in: Proc Natl Acad Sci USA 103:2465, 2006
46. Vandevoorde S, Lambert DM (2005) Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 11:2647-2668
47. Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257-268